Centre de Recherches en Cancérologie de Toulouse
In research, Centre de Recherches en Cancérologie de Toulouse stands highest in Medicine (#7,655 of 10,443 worldwide) and Health Sciences (#9,501 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Oncology and Molecular Biology — Oncology is 13.3× its share of world research.
- World rank, 2022–2025
- #11,682 of 28,054 · #12,268 all time
- Rank in France
- #468 of 1,422
- Research works
- 539 ▲ 82% vs 2013–17
- Citations
- 14k 25.4 per fractional work
- Top-10% rate
- 13.9% record average 16.5%
- Open access
- 45% world 28%
What is Centre de Recherches en Cancérologie de Toulouse known for in research?
The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works | All time |
|---|---|---|---|---|---|
| MedicineField | #7,655 of 10,443 | 14.1% | 88 | #9129 | |
| Health SciencesDomain | #9,501 of 11,982 | 13.7% | 91 | #11871 |
Each strip is that field’s whole ranked pool, with the notch where Centre de Recherches en Cancérologie de Toulouse sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
What does Centre de Recherches en Cancérologie de Toulouse specialise in?
Where its research is concentrated relative to its size: Oncology takes 13.3× the share of its output that it takes of world research.
- OncologySubfield · 24.2 works13×
- Molecular BiologySubfield · 28.9 works5.9×
Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.2×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 5.2×
- Immunology and Microbiology 5.1×
- Medicine 2.8×
- Pharmacology, Toxicology and Pharmaceutics 2.2×
- Veterinary 1.1×
- Neuroscience 0.7×
- Health Professions 0.7×
- Chemistry 0.5×
- Decision Sciences 0.5×
- Materials Science 0.4×
- Dentistry 0.4×
- Physics and Astronomy 0.4×
- Nursing 0.3×
- Engineering 0.2×
- Mathematics 0.2×
- Psychology 0.1×
- Computer Science 0.1×
- Agricultural and Biological Sciences 0.1×
- Environmental Science 0.1×
- Economics, Econometrics and Finance 0.1×
- Earth and Planetary Sciences 0.0×
- Social Sciences 0.0×
- Energy 0.0×
- Business, Management and Accounting 0.0×
Who are the top researchers at Centre de Recherches en Cancérologie de Toulouse?
Ranked on the composite score, Jean‐Emmanuel Sarry, Corinne Bousquet and Olivier Sordet lead among researchers whose main affiliation is Centre de Recherches en Cancérologie de Toulouse.
- 1 Jean‐Emmanuel Sarry France · #245,821 worldwide 92 citations · 26 works
- 2 Corinne Bousquet France · #277,059 worldwide 101 citations · 30 works
- 3 Olivier Sordet France · #654,224 worldwide 60 citations · 20 works
- 4 Julie Desrousseaux France · #778,022 worldwide 0 citations · 15 works
- 5 Christine Jean France · #799,031 worldwide 33 citations · 27 works
- 6 Julie Guillermet‐Guibert France · #1,002,624 worldwide 1 citations · 22 works
- 7 Véra Pancaldi France · #1,089,720 worldwide 40 citations · 23 works
- 8 Alexia Brunel France · #1,350,353 worldwide 0 citations · 18 works
- 9 Yvan Martineau France · #1,359,213 worldwide 7 citations · 15 works
Which keywords describe research at Centre de Recherches en Cancérologie de Toulouse?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Cancer, Prognostic Factors, Tumor Microenvironment, Targeted Therapy, Cancer Therapy and Neoadjuvant Therapy.
- Molecular Classification
- Cancer Progression
- EGFR Mutations
- Resistance Mechanisms
- Survival Analysis
- Cancer Genomics
- Immunity
- Hematopoietic Stem Cells
- Therapeutic Targets
- Drug Delivery
- Lymphoma
- Biomarkers
- Cancer Immunotherapy
- Gemcitabine
- Clinical Trials
- Neoadjuvant Therapy
- Inflammation
- Targeted Therapy
- Prognostic Factors
- Immunotherapy
- Chemotherapy
- Cancer
- Tumor Microenvironment
- Cancer Therapy
- Metabolism
- Genomic Instability
- Pancreatic Cancer
- Surgical Complications
- Metastasis
- Radiotherapy
- Tumor Regression
- Apoptosis
- Tumor Targeting
- PET Imaging
- Rituximab
- Mutational Signatures
- Genomic Profiling
- ALK Inhibitors
- Treatment Guidelines
- Genomic Stability
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy17▲ 15×21 topics
- Immunotherapy16▲ 14×17 topics
- Cancer15▲ 7.1×35 topics
- Prognostic Factors12▲ 16×12 topics
- Tumor Microenvironment11▲ 16×8 topics
- Targeted Therapy9▲ 26×5 topics
- Cancer Therapy8▲ 8.2×16 topics
- Inflammation6▲ 1.92×43 topics
- Metabolism6▲ 7.6×12 topics
- Neoadjuvant Therapy6▲ 16×5 topics
- Genomic Instability6▲ 34×3 topics
- Clinical Trials6▲ 5.6×7 topics
- Pancreatic Cancer6▲ 32×3 topics
- Gemcitabine6▲ 47×1 topic
- Surgical Complications6▲ 42×1 topic
- Cancer Immunotherapy5▲ 21×3 topics
- Metastasis5▲ 9.2×11 topics
- Biomarkers5▲ 4.5×17 topics
- Radiotherapy5▲ 7.8×9 topics
- Lymphoma5▲ 18×4 topics
- Tumor Regression4▲ 25×2 topics
- Drug Delivery4▲ 5.0×6 topics
- Apoptosis4▲ 8.5×14 topics
- Therapeutic Targets4▲ 17×6 topics
- Tumor Targeting4▲ 14×3 topics
- Hematopoietic Stem Cells4▲ 27×3 topics
- PET Imaging4▲ 14×4 topics
- Immunity4▲ 5.5×6 topics
- Rituximab4▲ 15×4 topics
- Cancer Genomics4▲ 30×1 topic
- Mutational Signatures4▲ 30×1 topic
- Survival Analysis4▲ 8.0×6 topics
- Genomic Profiling3▲ 21×2 topics
- Resistance Mechanisms3▲ 25×2 topics
- ALK Inhibitors3▲ 33×1 topic
- EGFR Mutations3▲ 33×1 topic
- Treatment Guidelines3▲ 9.5×2 topics
- Cancer Progression3▲ 10×6 topics
- Genomic Stability3▲ 51×2 topics
- Molecular Classification3▲ 12×4 topics
Which research topics does Centre de Recherches en Cancérologie de Toulouse publish most on?
By volume in 2022–2025: Pancreatic and Hepatic Oncology Research, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations and CAR-T cell therapy research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Pancreatic and Hepatic Oncology Research Oncology 6 works
- 2 Cancer Genomics and Diagnostics Cancer Research 4 works
- 3 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
- 4 CAR-T cell therapy research Oncology 3 works
- 5 Acute Myeloid Leukemia Research Hematology 3 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 3 works
- 7 RNA Research and Splicing Molecular Biology 2 works
- 8 Cancer Cells and Metastasis Oncology 2 works
- 9 DNA Repair Mechanisms Molecular Biology 2 works
- 10 Chronic Lymphocytic Leukemia Research Genetics 2 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Centre de Recherches en Cancérologie de Toulouse's research output changed?
Output in 2018–2022 was 82% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Toulouse
- Université Toulouse III - Paul Sabatier
- Université Fédérale de Toulouse Midi-Pyrénées
- Université Toulouse - Jean Jaurès
- Institut National Polytechnique de Toulouse
- Université Toulouse-I-Capitole
- Hôpital Rangueil
- Laboratoire d'Analyse et d'Architecture des Systèmes
- Hôpital Purpan
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.